[HTML][HTML] Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review …
SC Park, MY Choi, J Choi, E Park… - Clinical …, 2018 - ncbi.nlm.nih.gov
We aimed to compare the efficacy and safety of long-acting injectable (LAI) and oral second-
generation antipsychotics (SGAs) in treating schizophrenia by performing a systematic …
generation antipsychotics (SGAs) in treating schizophrenia by performing a systematic …
[HTML][HTML] A Digital intervention using daily financial incentives to increase medication adherence in severe mental illness: single-arm longitudinal pilot study
Background Medication nonadherence is prevalent in severe mental illness and is
associated with multiple negative outcomes. Mobile technology and financial incentives …
associated with multiple negative outcomes. Mobile technology and financial incentives …
Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder
A Abdel‐Baki, D Thibault, S Medrano… - Early Intervention in …, 2020 - Wiley Online Library
Aim Substance use disorder (SUD) is highly prevalent among patients with first‐episode
psychosis (FEP) and associated with poor adherence and worst treatment outcomes …
psychosis (FEP) and associated with poor adherence and worst treatment outcomes …
Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome
AT Olagunju, SR Clark… - Australian & New Zealand …, 2019 - journals.sagepub.com
Objective: Impairment in psychosocial function is common in schizophrenia. Long-acting
injectable atypical antipsychotics are thought to enhance psychosocial function by boosting …
injectable atypical antipsychotics are thought to enhance psychosocial function by boosting …
A multiple imputation strategy for sequential multiple assignment randomized trials
Sequential multiple assignment randomized trials (SMARTs) are increasingly being used to
inform clinical and intervention science. In a SMART, each patient is repeatedly randomized …
inform clinical and intervention science. In a SMART, each patient is repeatedly randomized …
[HTML][HTML] Expert consensus survey on digital health tools for patients with serious mental illness: optimizing for user characteristics and user support
A Hatch, JE Hoffman, R Ross, JP Docherty - JMIR Mental Health, 2018 - mental.jmir.org
Background: Digital technology is increasingly being used to enhance health care in various
areas of medicine. In the area of serious mental illness, it is important to understand the …
areas of medicine. In the area of serious mental illness, it is important to understand the …
[HTML][HTML] Early signs monitoring to prevent relapse in psychosis and promote well-being, engagement, and recovery: protocol for a feasibility cluster randomized …
A Gumley, S Bradstreet, J Ainsworth… - JMIR research …, 2020 - researchprotocols.org
Background: Relapse in schizophrenia is a major cause of distress and disability and is
predicted by changes in symptoms such as anxiety, depression, and suspiciousness (early …
predicted by changes in symptoms such as anxiety, depression, and suspiciousness (early …
The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design
Up to 80% of first-episode psychosis patients suffer a relapse within five years of the
remission. Relapse should be an important focus of prevention given the potential harm to …
remission. Relapse should be an important focus of prevention given the potential harm to …
Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
JM Kane, R Sanchez, J Zhao, AR Duca… - Journal of Medical …, 2013 - Taylor & Francis
Objective: To report the design and preliminary results of a mirror-image study comparing
total psychiatric hospitalisation rates pre-and post-switch to aripiprazole once-monthly, an …
total psychiatric hospitalisation rates pre-and post-switch to aripiprazole once-monthly, an …
Improving medication-related outcomes for patients with psychiatric and neurologic disorders: value of psychiatric pharmacists as part of the health care team
LW Goldstone, BA DiPaula… - The Mental Health …, 2015 - meridian.allenpress.com
Psychiatric pharmacists have specialized knowledge, skills, and training or substantial
experience working with patients with psychiatric or neurologic disorders. As part of the …
experience working with patients with psychiatric or neurologic disorders. As part of the …